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Abstract
Background: Nearly one-third of the United States adult population suffers from hypertension. Hydrochlorothiazide
(HCTZ), one of the most commonly used medications to treat hypertension, has variable efficacy. The renal
epithelial sodium channel (ENaC) provides a mechanism for fine-tuning sodium excretion, and is a major regulator
of blood pressure homeostasis. DOT1L, MLLT3, SIRT1, and SGK1 encode genes in a pathway that controls
methylation of the histone H3 globular domain at lysine 79 (H3K79), thereby modulating expression of the ENaCa
subunit. This study aimed to determine the role of variation in these regulatory genes on blood pressure response
to HCTZ, and secondarily, untreated blood pressure.
Methods: We investigated associations between genetic variations in this candidate pathway and HCTZ blood
pressure response in two separate hypertensive cohorts (clinicaltrials.gov NCT00246519 and NCT00005520). In a
secondary, exploratory analysis, we measured associations between these same genetic variations and untreated
blood pressure. Associations were measured by linear regression, with only associations with P ≤ 0.01 in one
cohort and replication by P ≤ 0.05 in the other cohort considered significant.
Results: In one cohort, a polymorphism in DOT1L (rs2269879) was strongly associated with greater systolic (P =
0.0002) and diastolic (P = 0.0016) blood pressure response to hydrochlorothiazide in Caucasians. However, this
association was not replicated in the other cohort. When untreated blood pressure levels were analyzed, we found
directionally similar associations between a polymorphism in MLLT3 (rs12350051) and greater untreated systolic (P
< 0.01 in both cohorts) and diastolic (P < 0.05 in both cohorts) blood pressure levels in both cohorts. However,
when further replication was attempted in a third hypertensive cohort and in smaller, normotensive samples,
significant associations were not observed.
Conclusions: Our data suggest polymorphisms in DOT1L, MLLT3, SIRT1, and SGK1 are not likely associated with
blood pressure response to HCTZ. However, a possibility exists that rs2269879 in DOT1L could be associated with
HCTZ response in Caucasians. Additionally, exploratory analyses suggest rs12350051 in MLLT3 may be associated
with untreated blood pressure in African-Americans. Replication efforts are needed to verify roles for these
polymorphisms in human blood pressure regulation.
Keywords: Pharmacogenomics, Pharmacogenetics, hydrochlorothiazide, hypertension, blood pressure, DOT1L, SIRT1,
MLLT3, SGK1, histone methylation
* Correspondence: juliod@uic.edu
1Center for Pharmacogenomics and Department of Pharmacotherapy and
Translational Research, University of Florida, Gainesville, FL 32610, USA
Full list of author information is available at the end of the article
Duarte et al. Journal of Translational Medicine 2012, 10:56
http://www.translational-medicine.com/content/10/1/56
© 2012 Duarte et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Hydrochlorothiazide (HCTZ) is one of the most com-
monly prescribed antihypertensive drug in the US, with
approximately 118 million prescriptions dispensed in
2010, either alone or combined with another antihyper-
tensive [1,2]. HCTZ and other thiazide diuretics are
recommended by current hypertension treatment guide-
lines in the United States as first-line treatment for
most patients with uncomplicated essential hyperten-
sion, and are strongly recommended for all patients
requiring two or more antihypertensives for blood pres-
sure control [3].
Patient response to thiazides varies widely, with differ-
ential responses between and within races [4]. Because
of this, clinicians have difficulty predicting which
patients will achieve good blood pressure response with
thiazide treatment. Pharmacogenetic studies can not
only help explain this variability in drug response, but
can also provide further information on the mechanistic
basis of thiazides.
Thiazides achieve their initial diuretic action by pre-
venting renal sodium reabsorption via inhibition of the
Na
+/Cl
- cotransporter (NCC) in the distal convoluted
tubule [5-7]. However, the mechanism by which thia-
zides chronically lower blood pressure remains poorly
understood. Also involved in sodium reabsorption is the
distally-located epithelial sodium channel (ENaC).
Although ENaC contributes to the reabsorption of
approximately 5% of total filtered sodium load, it pro-
vides a fine-tuning mechanism for sodium, body fluid
volume, and, ultimately, blood pressure homeostasis [8].
Because ENaC is distal to NCC in the nephron, inhibi-
tion of NCC, such as occurs with thiazide therapy,
results in altered ion concentrations in the tubular
lumen, particularly increased sodium concentrations at
ENaC-expressed regions. Consequently, the clinical
effect of variations in ENaC expression could be magni-
fied in thiazide-treated patients. In fact, evidence already
exists showing association between variation in
NEDD4L, a gene involved in ENaC regulation, and
blood pressure response to diuretics [9]. In addition,
pharmacogenetic research has previously implicated
ENaC in thiazide response, as polymorphisms in
SCNN1G (which encodes the ENaCg subunit) have been
associated with HCTZ response [10,11]. In addition,
ENaC is expressed in the vascular smooth muscle and
may also play some role in regulating vascular resistance
[12].
An epigenetic pathway was recently discovered that
regulates ENaCa expression in the kidney by methyla-
tion of histone protein H3 at lysine 79 (H3K79) [13-15].
At the center of this pathway is a complex including the
methyltransferase Disruptor of telomeric silencing 1
(Dot1) and DNA-binding protein ALL1 fused gene from
chromosome 9 (Af9) [15]. Af9 (in humans, encoded by
MLLT3) binds to the ENaCa promoter and localizes
Dot1 for di- and tri-methylation at H3 Lys79, which is
associated with ENaCa gene repression [16]. This
repression can be prevented by Serum/glucocorticoid-
induced kinase (encoded by SGK1), which disrupts the
assembly of the Af9/Dot1 complex [14]. Evidence indi-
cates that the deacetylase Sirtuin-1 (encoded by SIRT1)
can also form a complex with Dot1 to decrease ENaCa
expression. However, the mechanism for this interaction
is still unclear [17].
We hypothesized that genetic variation in this epige-
netic regulatory pathway plays a role in the antihyper-
tensive effects of thiazides, through its regulation of
ENaC. Secondarily, we hypothesized that variation in
this pathway affects human blood pressure homeostasis.
To test the first hypothesis, we evaluated whether poly-
morphisms in DOT1L, MLLT3, SIRT1,a n dSGK1 affect
clinical blood pressure response to HCTZ in well-
defined clinical cohorts. To test the second, we assessed
associations of these polymorphisms with untreated
clinical blood pressures as an exploratory analysis.
Methods
Participants
Study participants arose from the Pharmacogenomic
Evaluation of Antihypertensive Responses (PEAR; clini-
caltrials.gov #NCT00246519) and the Genetic Epide-
miology of Responses to Antihypertensives (GERA;
clinicaltrials.gov #NCT00005520). Both studies were
approved by the institutional review boards at each cen-
ter where they were conducted, and all subjects pro-
vided informed, written consent before being screened
for enrollment.
PEAR was a multi-center clinical trial examining the
role of genetic variability on blood pressure response to
HCTZ and/or atenolol [18]. Men and women of any
race between the ages of 17 and 65 with essential hyper-
tension (clinic diastolic blood pressure ≥ 90 mmHg, ≤
110 mmHg) were recruited to participate. After a four-
week antihypertensive washout, included participants
were randomized to receive either HCTZ 12.5 mg daily
or atenolol 50 mg daily, with most receiving dose escala-
tions to 25 mg and 100 mg, respectively for blood pres-
sure greater than 120/70 mmHg. To assure a four-week
washout sufficiently erased blood pressure effects of any
previous antihypertensive treatments, we confirmed that
post-washout blood pressure levels in previously-treated
participants were nearly identical to those who had
never received antihypertensive medication. After nine
weeks, blood pressure response was assessed and for
blood pressure greater than 120/70 mmHg, the other
Duarte et al. Journal of Translational Medicine 2012, 10:56
http://www.translational-medicine.com/content/10/1/56
Page 2 of 9study drug was added with another dose titration and
response assessment after six to nine weeks. Participants
were not given sodium restrictions, but were counseled
to maintain consistent dietary intakes. The primary
response phenotype was home blood pressure, which
participants were required to take in triplicate upon ris-
ing and before retiring at least five of seven days prior
to their blood pressure assessment visit. The coefficients
of variance were approximately 7% for both systolic and
diastolic measurements. The first 297 self-reported Cau-
casians and African-Americans to complete HCTZ
monotherapy (PEAR HCTZ) are included in this report.
In these participants randomized to HCTZ, greater than
90% received dose increases to 25 mg. For Caucasian
and African-Americans randomized to atenolol (PEAR
ATEN), 374 participants were included for untreated
blood pressure analyses.
GERA was a two-center clinical trial designed to
determine whether polymorphisms in renin-angiotensin-
aldosterone system genes were predictive of the blood
pressure response to HCTZ [19]. Briefly, participants
were self-reported non-Hispanic Caucasians and Afri-
can-Americans between the ages of 30 and 59 who had
blood pressure greater than 140/90 mmHg or a previous
diagnosis of essential hypertension and current antihy-
pertensive prescription. Previously treated hypertensives
had all antihypertensive drugs discontinued for four
weeks, then were assessed for blood pressure at baseline.
If diastolic blood pressure remained between 90 and 110
mmHg, participants were included in the study and
treated with HCTZ 25 mg daily for four weeks. Partici-
pants were counseled to stabilize sodium intake at about
1 mmol/kg/day beginning at washout and continuing
throughout the study period. All blood pressure mea-
surements were made in a clinic setting.
Two normotensive samples were also used in an
attempt to replicate untreated blood pressure associa-
tions found in GERA and PEAR African-Americans.
The first sample drawn from was the Ethnic Pain Sensi-
tivity trial, a single center study designed to examine
ethnic differences in pain sensitivity [20]. 206 healthy
men and women between the ages of 18-53, represent-
ing multiple ethnic groups, were enrolled at the Univer-
sity of Florida. Mean resting systolic and diastolic blood
pressure, mean arterial pressure, and mean resting heart
rate were measured in each participant. For replication
purposes, 88 available African-American participants
were included in analyses. The second sample was a
hypertension database from t h eU n i v e r s i t yo fF l o r i d a
that enrolled 730 participants, both hypertensive and
normotensive. Normotensive participants (systolic blood
below 140 mm Hg and diastolic blood pressure below
90 mm Hg) were never diagnosed with high blood pres-
sure and had no parents, siblings, or children with high
blood pressure diagnosed before age 65. For replication
purposes, 121 available African-American normotensives
were included in analyses.
Selection of polymorphisms and determination of
genotypes
A tagSNP approach was used to assure maximum cover-
age of common SNPs in each candidate gene region. A
tagSNP selection tool using the Multipop-TagSelect
algorithm [21] provided online by the Genome Variation
Server http://gvs.gs.washington.edu/GVS/ was queried
for the genetic regions of DOT1L, MLLT3, SIRT1,a n d
SGK1 in the HapMap YRI (African Ancestry) and CEPH
(European Ancestry) populations. SNPs with a minor
allele frequency less than 5% were excluded. The Gen-
ome Variation Server provided a comprehensive list of
144 SNPs meeting these criteria which tagged all four
gene regions.
To more precisely investigate the strongest candidate
SNPs, putative functional SNPs (pfSNPs) were added to
the lists generated by the Genome Variation Server.
These were computed in silico by two separate pro-
grams, Pupasuite [22] and FastSNP [23]. From this com-
bined list of pfSNPs, those with a minor allele frequency
greater than 0.05 for either African or European ances-
try were added to the already established tagSNP list.
The resulting final list contained 180 SNPs to genotype
(Additional file 1; Table S1).
Genotypes in HCTZ-treated GERA and PEAR partici-
pants were determined using a custom GoldenGate
Assay for the BeadXpress Reader System (Illumina Inc.,
San Diego, CA). Genotyping was carried out according
to the manufacturer’s protocol. Raw data conversion
and quality control were completed in GenomeStudio
software (Illumina Inc., San Diego, CA). Samples were
excluded if their genotype call rate was below 90%. Indi-
vidual SNPs were excluded from analysis if they were
monomorphic in our cohorts, their call frequencies were
below 75%, or their GenTrain scores were less than 0.3.
For untreated blood pressure replication analyses, gen-
otypes were determined using Taqman SNP Genotyping
Assays and the Taqman 7900HT Real Time PCR System
(Applied Biosystems, Foster City, CA) according to the
manufacturer’s protocol.
Statistical methods
Associations between genotype and blood pressure
responses to HCTZ were tested by linear regression
after adjustment for covariates, including gender, age,
and untreated blood pressure. Associations between
untreated systolic blood pressure and diastolic blood
pressure were tested in the same manner as described
for HCTZ response, except covariate adjustments
included only gender and age. Statistical analyses were
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tute, Cary, NC).
Because of the large number of SNPs tested, adjust-
ments for multiple comparisons were necessary to avoid
false positives. A Bonferroni correction, assuming 180
independent tests, would require a P ≤ 0.00028 for sig-
nificance (0.05/180 = 0.00028). However, the SNPs ana-
lyzed are strong biological candidates, and do not
represent independent tests due to linkage disequili-
brium. Additionally, replication of findings is essential in
genetic association studies. In our analyses, SNPs were
considered significant if they associated with HCTZ
blood pressure response in either GERA or PEAR with
P ≤ 0.01, replicated with P ≤ 0.05 in the other study
group, and had matching directions of effect. With this
replication strategy, the overall P-value threshold for sig-
nificance is 0.01 × 0.05 × 0.5 (for matching direction of
effect) = 0.00025, which therefore meets the Bonferroni
criterion, as similarly justified previously [24].
As a quality control procedure, Hardy-Weinberg equi-
librium was tested via c
2 analysis separately by race and
study group. Those SNPs with Hardy-Weinberg equili-
brium P-values less than a Bonferroni-corrected 0.00028
were flagged and analyzed under suspicion of genotyp-
ing error.
Results
Study cohorts
Baseline characteristics were similar among both study
cohorts (Table 1). Both normotensive replication
cohorts varied from the study cohorts in racial make-up
and untreated blood pressure (by design), and also var-
ied slightly from all other groups in age and BMI. In
PEAR, HCTZ treatment decreased blood pressure by
approximately 12/7 mmHg in African Americans and 8/
4 mmHg in Caucasians. In GERA, HCTZ treatment
decreased blood pressure by approximately 18/9 mmHg
in African Americans and 11/6 mmHg in Caucasians.
GERA - Genetic Epidemiology of Responses to Anti-
hypertensives trial, PEAR HCTZ - Randomized to
HCTZ in the Pharmacogenomic Evaluation of Antihy-
pertensive Responses trial, PEAR ATEN - Randomized
to atenolol in the Pharmacogenomic Evaluation of Anti-
hypertensive Responses trial, EPS AA population - Afri-
can Americans from the Ethic Pain Sensitivity trial,
HTNDB AA Normotensives - Normotensive African
Americans from a University of Florida hypertension
database, BP - blood pressure, N/A - Not Available.
Out of a total 180 SNPs genotyped with the Golden-
Gate assay, six SNPs were excluded for having a SNP
call frequency less than 75% or a GenTrain score less
than 0.3. An additional two SNPs failed these quality
controls in GERA only, so were analyzed exclusively in
PEAR. In GERA, 19 participant samples were excluded
from analysis because of low genotype call rates (<
90%). In PEAR, one participant sample was excluded
from analyses because of low call rates. Taqman geno-
typing of rs12350051 was completed in replication sam-
ples with approximately 7% duplication, revealing 98%
concordance. Both rs2269879 and rs12350051 were in
Hardy-Weinberg equilibrium in all groups analyzed.
Association of candidate gene variation with
hydrochlorothiazide response
A Manhattan plot of -log P-values for genetic associa-
tions with blood pressure response in GERA and PEAR
H C T Z( F i g u r e1 )i n d i c a t en oS N Pa s s o c i a t i o n sw e r e
replicated according to predetermined criteria for signif-
icance. The DOT1L SNP rs2269879 came the closest to
our criteria for a significant association. The variant T
Table 1 Baseline demographics of GERA and PEAR clinical cohorts
GERA PEAR
HCTZ
PEAR
ATEN
HTNDB AA Normotensives EPS AA Population
N 583 297 374 121 88
Age (y) 48.2 ± 6.7 50.3 ± 8.9 48.6 ± 9.2 45.1 ± 7.1 22.7 ± 5.1
Sex (% female) 47.2 51.2 57.7 52.9 51.1
Race (%)
Caucasian 50.3 57.1 58.9 0 0
African-American 49.7 42.9 41.1 100 100
BMI (kg/m
2) 31.3 ± 6.0 30.8 ± 5.6 31.0 ± 6.2 30.1 ± 6.8 25.2 ± 4.3
Mean Clinic BP
Systolic (mmHg) 146.0 ± 14.4 152.6 ± 13.0 151.4 ± 12.4 118.3 ± 9.1 122.5 ± 8.9
Diastolic (mmHg) 96.1 ± 5.4 98.7 ± 6.1 98.3 ± 6.2 76.7 ± 6.3 68.4 ± 5.9
Mean Home BP
Systolic (mmHg) N/A 146.7 ± 11.2 145.2 ± 9.8 N/A N/A
Diastolic (mmHg) N/A 94.3 ± 6.2 93.5 ± 6.0 N/A N/A
Values are listed as mean ± SD
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greater mean systolic (P = 0.0002) and a 3.5 mmHg
greater mean diastolic (P = 0.0016) response to HCTZ
in PEAR HCTZ Caucasians (Figure 2), while no associa-
tion was found in PEAR HCTZ African-Americans.
Blood pressure response associations in GERA Cauca-
sians possessed the same direction of effect as those in
PEAR HCTZ (Figure 2), but were not statistically signifi-
cant (systolic P = 0.73, diastolic P = 0.29). Because
GERA P-values did not meet our predetermined criteria
for significance, this SNP was not considered a repli-
cated association.
Association of candidate gene variation with untreated
blood pressure
In a pre-defined secondary analysis, we observed asso-
ciations between baseline, untreated blood pressure and
rs12350051 (in MLLT3) genotype in both PEAR HCTZ
(systolic P = 0.005, diastolic P =0 . 0 4 9 )a n dG E R AA f r i -
can-Americans (systolic P = 0.001, diastolic P = 0.010)
at the pre-defined thresholds for association and replica-
tion (Figure 3). African-Americans with the variant C
allele at rs12350051 had mean untreated systolic blood
pressures 6.4 mmHg higher in PEAR HCTZ and 6.9
mmHg higher in GERA than those with the T/T geno-
type (Figure 4). Mean untreated diastolic blood pres-
sures were 2.8 mmHg higher in PEAR HCTZ and 1.8
mmHg higher in GERA (Figure 4). No association was
observed in Caucasians.
Since this discovered association was with untreated
blood pressure, baseline data could be used from Afri-
can-Americans randomized to atenolol in PEAR ATEN
as a further replication. While the untreated blood pres-
sures of PEAR ATEN African-Americans followed a
similar trend to GERA and PEAR HCTZ African-Ameri-
cans, the means between genotype groups differed by
less than 1 mmHg for both systolic and diastolic blood
pressures and the difference was not statistically signifi-
cant (Figure 5). Further association testing in the Afri-
can-American normotensive replication samples
revealed no associations with untreated blood pressure
(data not shown).
Discussion
We investigated associations in a candidate pathway for
HCTZ blood pressure response, which controls expres-
sion of ENaC. Our study showed no association between
common variation in DOT1L, MLLT3, SIRT1,o rSGK1
and blood pressure responses to HCTZ that met our
pre-defined criteria for significance. In an exploratory
analysis, we also evaluated the role of SNPs in this path-
way on untreated blood pressure and identified
rs12350051 in MLLT3 as being associated with baseline
blood pressure in both GERA and PEAR African-Ameri-
cans. However, in another PEAR and two normotensive
cohorts, this association did not replicate.
The strongest pharmacogenetic association with
HCTZ response was with rs2269879 in DOT1L, and
Figure 1 A s s o c i a t i o no fc a n d i d a t eS N P sw i t hb l o o dp r e s s u r er e s p o n s et oH C T Zi nG E R Aa n dP E A RH C T Zc o h o r t s . The lower line
represents P = 0.05, while the higher line represents P = 0.01. B - African American, W - Caucasian, BL - Untreated, SBP - systolic blood pressure
response, DBP - diastolic blood pressure response.
Figure 2 Blood pressure response to HCTZ by rs2269879
genotype in GERA and PEAR in Caucasian samples. Adjusted for
age, gender, and untreated blood pressure. Error bars indicate
standard error. SBP - Systolic blood pressure; DBP - diastolic blood
pressure; ‡ - P ≤ 0.001; † - P ≤ 0.01.
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systolic and diastolic response in GERA were direction-
ally consistent, but nonsignificant. Located in intron 7,
rs2269879 was chosen for genotyping as a tagSNP.
Upon review in the HapMap CEPH population, the SNP
was found to be in perfect linkage with rs8113528 (r
2 =
1.0), in intron 3. FastSNP showed the variant A allele at
rs8113528 creates a possible binding site for p300, tran-
scriptional co-activator that functions as a histone acet-
yltransferase. Additionally, UCSC Genome Browser
http://genome.ucsc.edu/ indicates rs8113528 exists in an
area surrounded by moderate histone acetylation.
Because the association only met the significance
threshold in PEAR, and did not replicate in GERA, we
cannot rule out that this is a chance finding. One reason
for a lack of replication in GERA may be that the effect
of this SNP can only be detected using home blood
pressure. PEAR was the only study with the home blood
pressure phenotype available. We decided ap r i o r ito
use it as the response phenotype in PEAR because home
blood pressure is a more accurate phenotype, as home
blood pressure predicts cardiovascular risk better than
office blood pressure [25,26]. In addition, we previously
found ambulatory blood pressure measurement, another
potentially better predictor of cardiovascular risk, corre-
lated with home blood pressure more than with office
blood pressure in a subset of PEAR participants [27].
PEAR home blood pressure entries were averages of
multiple measurements spanning at least five days, thus
they likely give a better estimate of participants’ actual
blood pressures. Home blood pressure is also a more
precise phenotype, as evidenced by the smaller standard
deviations in home systolic blood pressure measure-
ments we observed in PEAR compared with office mea-
surements (Table 1 systolic: P < 0.001, diastolic: P =
0.689). Office measurements, the only blood pressure
phenotypes available in GERA, may not possess high
enough fidelity to detect this association with
rs2269879. Supporting this theory, we observed similar,
Figure 3 Association of candidate SNPs with untreated blood pressure in GERA and PEAR HCTZ cohorts. The lower line represents P =
0.05, while the higher line represents P = 0.01. B - African American, W - Caucasian, BL - Untreated, SBP - systolic blood pressure, DBP - diastolic
blood pressure.
Figure 4 Untreated blood pressure by rs12350051 genotype in
GERA and PEAR HCTZ African-American samples. Adjusted for
age and gender. Error bars indicate standard error. SBP - Systolic
blood pressure; DBP - diastolic blood pressure; † - P (trend) ≤ 0.01; *
- P (trend) ≤ 0.05.
Figure 5 Untreated blood pressure by rs12350051 genotype in
PEAR ATEN African-American sample. Adjusted for age and
gender. Error bars indicate standard error. SBP - Systolic blood
pressure; DBP - diastolic blood pressure.
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response in PEAR. Perhaps if another large hypertensive
cohort, prospectively treated with HCTZ, becomes
obtainable for analysis of home blood pressure
responses, the association we found could be tested
again for replication.
The lack of association we found with HCTZ response
suggests that genotyping polymorphisms in this pathway
would likely not help predict patient response to thia-
zide diuretics. The likelihood that common SNP associa-
tions were missed with DOT1L, MLLT3, SIRT1, SGK1
and blood pressure associations is low. TagSNPs within
5000 bases of each candidate gene were selected to try
to detect any possible cis-regulatory regions. Great effort
was spent on identifying pfSNPs in silico for each candi-
date gene, which were not required to be in the pre-
defined gene region for tagSNP development. However,
only SNPs with a minor allele frequency of 0.05 were
considered for genotyping, so our study cannot rule out
very rare SNPs in the candidate genes with large effect
sizes affecting blood pressure response. Additionally, our
data do not rule out whether or not this pathway plays
a n yr o l et h i a z i d er e s p o n s e .I fH C T Zd i dh a v es o m e
small effect on H3K79 methylation, redundancy in
ENaCa regulation [28] could conceivably overcome the
changes in H3K79 methylation and leave behind no
measurable change in patient blood pressure response.
Little is known about the effect of this histone H3K79
methylation pathway on blood pressure regulation in
humans, so exploratory analyses testing associations in
untreated blood pressure phenotypes could also provide
valuable information. The SNP that associated and repli-
cated with untreated blood pressure was rs12350051 in
MLLT3. It was chosen as a tagSNP, and is located in
intron 2, with no linkage to any known functional SNPs.
In silico, rs12350051 was not observed in any known
miRNA sequences, transcription factor binding sites,
exonic splice sites, splice enhancer, or silencer
sequences. Because the same blood pressure association
was not seen in Caucasians, one possibility could be
that this SNP is in high linkage disequilibrium with an
undiscovered functional polymorphism in African-
Americans.
One would expect using a patient population with a
wide range of blood pressures to be the best method to
detect genetic associations with untreated blood pres-
sure. So the fact that untreated blood pressure associa-
tions were seen in PEAR and GERA is somewhat
surprising, as these studies enrolled hypertensives span-
ning a relatively small blood pressure range. This was
one of the reasons we attempted to replicate these find-
ings in normotensive blood pressure ranges not repre-
sented in PEAR and GERA. However, the normotensive
groups also had a narrow blood pressure range. The fact
that no replication was observed in normotensives could
be because of this narrow blood pressure range, the fact
that they were younger, the differences in study proto-
cols, leading to differences in blood pressure measure-
ment precision, or the sample sizes were too small and
lacked the power to detect the effect we observed in the
larger hypertensive cohorts. Another possibility is that
perhaps the effect of this SNP is easier to detect or only
exerts an effect with higher blood pressures.
Our findings are not the first to detect associations
between this H3K79 methylation pathway and blood
pressure regulation. Dot1 conditional knockout mice
were shown to exhibit salt sensitive hypertension [29].
Conversely, mice null for Af17,w h i c hh a sb e e ns h o w n
to compete with Af9 for Dot1 binding at the ENaCa
promoter, [30] exhibit renal salt wasting and hypoten-
sion with diminished renal H3K79 methylation and
renal ENaCa gene expression [31]. Also, Sirtuin-1 dea-
cetylation of endothelial nitric oxide synthase [32] has
been suggested as a possible mechanism for the blood
pressure reduction seen during caloric restriction, a
well-known inducer of Sirtuin-1 [33].
Conclusions
In conclusion, associations likely do not exist between
common variation in MLLT3, SIRT1,o rSGK1 and
blood pressure responses to HCTZ in hypertensives.
One SNP in DOT1L (rs2269879) could play a role in
HCTZ response, but requires further investigation to
replicate the association found in PEAR. Additionally,
rs12350051 in MLLT3 was associated with untreated
blood pressure in African-American hypertensive indi-
viduals. Because this was an exploratory analysis, and
the association was not replicated in smaller normo-
tensive samples, questions remain as to whether this
polymorphism is involved in the blood pressure regu-
lation of normotensives, and the mechanism by which
rs12350051 exerts an effect on blood pressure.
Further study in clinical populations with broader
blood pressure ranges would help answer these
questions.
Additional material
Additional file 1: Supplementary Table 1. SNPs genotyped in SGK1,
DOT1L, SIRT1, and MLLT3 gene regions.
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